Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;27(5):790-792.
doi: 10.1038/s41591-021-01316-7. Epub 2021 Mar 29.

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Matan Levine-Tiefenbrun #  1 , Idan Yelin #  2 , Rachel Katz  3 , Esma Herzel  3 , Ziv Golan  4 , Licita Schreiber  4 , Tamar Wolf  4 , Varda Nadler  4 , Amir Ben-Tov  3   5 , Jacob Kuint  3   5 , Sivan Gazit  3 , Tal Patalon  3 , Gabriel Chodick  3   5 , Roy Kishony  6   7
Affiliations

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Matan Levine-Tiefenbrun et al. Nat Med. 2021 May.

Abstract

Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19) vaccines might reduce viral load in breakthrough infection and thereby further suppress onward transmission. In this analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine, we found that the viral load was substantially reduced for infections occurring 12-37 d after the first dose of vaccine. These reduced viral loads hint at a potentially lower infectiousness, further contributing to vaccine effect on virus spread.

PubMed Disclaimer

References

    1. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). - DOI
    1. Chodcik, G. et al. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13–24 days after immunization: real-world evidence. Preprint at medRxiv https://doi.org/10.1101/2021.01.27.21250612 (2021).
    1. Gallagher, M. E. et al. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates. Nat. Med. 27, 4–5 (2021). - DOI
    1. Rubin, E. J. & Longo, D. L. SARS-CoV-2 vaccination: an ounce (actually, much less) of prevention. N. Engl. J. Med. 383, 2677–2678 (2020). - DOI
    1. Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 129 (2021).

Publication types